Stocks · Healthcare · Medical - Devices
Edwards Lifesciences Corporation EW
$85.15 -0.05% Close, Oct 2, 2026 · NYSE · Market cap $49.03B
High qualityLow risk
Next earnings report: Oct 29, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Diluted EPS over the last four quarters was $1.74, down 75.0% year over year.
- The shares trade at 48.9× trailing earnings, higher than 90% of the company's own readings over the past five years.
- Revenue over the last four quarters was $6.51B, up 14.6% from a year earlier.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Top 40%
- EPS growth (TTM, YoY)Bottom 21%
- FCF growth (TTM, YoY)Top 12%
- Revenue growth, 3-year CAGRBottom 35%
- Revenue growth accelerationTop 38%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 14%
- Gross marginTop 33%
- Operating marginTop 8%
- Cash conversion (OCF / net income)Top 42%
- Accruals (lower is better)Bottom 43%
- Net debt / EBITDA (lower is better)Top 16%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 24%
- Free-cash-flow yieldTop 26%
- EBITDA / enterprise valueTop 30%
- Sales / enterprise valueBottom 38%
- P/E vs own 5-year history (lower is better)Bottom 11%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 48%
- 6-month returnBottom 48%
- 1-year return vs S&P 500Bottom 49%
- Distance from 52-week highTop 18%
- Trend checklist (0–4)Top 39%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 48%
- Consecutive EPS beatsTop 35%
- Share of analysts rating BuyBottom 37%
- Upside to consensus price targetBottom 26%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 3%
- Maximum drawdown, 3 yearsTop 12%
- Beta vs S&P 500 (lower is better)Top 15%
- Net debt / EBITDA (lower is better)Top 16%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 13.8% | 14.6% | ↑ |
| EPS growth (YoY) | -73.1% | -75.0% | ↓ |
| Gross margin | 78.9% | 78.0% | ↓ |
| Operating margin | 26.2% | 28.1% | ↑ |
| FCF margin | 10.7% | 22.0% | ↑ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 14.6% | 13.8% | ↑ | Top 40% |
| EPS growth (TTM, YoY) | -75.0% | -73.1% | ↓ | Bottom 21% |
| Gross margin | 78.0% | 78.9% | ↓ | Top 33% |
| Operating margin | 28.1% | 26.2% | ↑ | Top 8% |
| Net margin | 15.4% | 72.9% | ↓ | — |
| Free-cash-flow margin | 22.0% | 10.7% | ↑ | — |
| Return on invested capital | 10.2% | — | Top 14% | |
| Revenue growth, 3-year CAGR | 4.1% | — | Bottom 35% |
Quality of earnings and balance sheet
- Cash conversion (OCF / net income)Above 1× means profits are backed by cash.
- 1.71×
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -5.2%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 2.6%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- -8.7 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- -1.43×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- 0.62%
- Shareholder yield
- 0.62%
- Share count change, 1 year
- -1.8%
- Share count change, 3-year CAGR
- -1.8%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 4, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 2
- Beats in the last 8 reports
- 7 of 8
- Average EPS surprise, last 4
- +4.6%
- Average 2-day reaction, last 8
- -0.5%
- Positive 20 days after report
- 6 of 8
Analysts
- Consensus price target
- $101.70
- Target vs current price
- +19.4%
- Analysts with a rating
- 49
- Share rating Buy or Strong Buy
- 67%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Jul 23, 2026 | +5.0% | -0.7% | +1.6% | +9.4% | — |
| Apr 23, 2026 | +7.0% | -2.2% | -0.4% | +1.8% | +4.3% |
| Feb 10, 2026 | -6.1% | +0.3% | +2.1% | +11.7% | +8.3% |
| Oct 30, 2025 | +12.4% | +1.0% | +0.2% | +4.9% | +1.1% |
| Jul 24, 2025 | +7.4% | -1.4% | +5.5% | +5.8% | -5.5% |
| Apr 23, 2025 | +7.4% | -0.2% | +8.0% | +10.2% | +8.3% |
| Feb 11, 2025 | +7.1% | -0.3% | +6.4% | -3.8% | +5.5% |
| Oct 24, 2024 | +0.8% | -0.4% | -2.8% | -1.5% | -2.2% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Jul 23, 2026 | $0.78 | $0.74 | +5.0% | $1.74B |
| Apr 23, 2026 | $0.78 | $0.73 | +7.0% | $1.65B |
| Feb 10, 2026 | $0.58 | $0.62 | -6.1% | $1.57B |
| Oct 30, 2025 | $0.67 | $0.60 | +12.4% | $1.55B |
| Jul 24, 2025 | $0.67 | $0.62 | +7.4% | $1.53B |
| Apr 23, 2025 | $0.64 | $0.60 | +7.4% | $1.41B |
| Feb 11, 2025 | $0.59 | $0.55 | +7.1% | $1.39B |
| Oct 24, 2024 | $0.67 | $0.67 | +0.8% | $1.35B |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| P/E (trailing) | 48.9× | 37.0× | 90th | Top 24% |
| P/E (forward) | 28.4× | — | — | — |
| EV / EBITDA | 30.4× | — | — | Top 30% |
| EV / Sales | 7.19× | — | — | Bottom 38% |
| Free-cash-flow yield | 2.92% | — | — | Top 26% |
| Earnings yield | 2.04% | — | — | Top 24% |
P/E over the past five years
Range 9.5× – 51.5× since Jun 30, 2021. Each point: price on the filing date divided by trailing-twelve-month EPS known then.
What moved the stock over the past year
- Price return, 1 year
- +11.6%
- Earnings per share growth (TTM)
- -75.0%
- Change in P/E multiple
- +355.3%
Most of the move came from a change in the valuation multiple.
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 15
- 50-day average slope (20 days)
- -1.3%
- 200-day average slope (20 days)
- +0.2%
- Distance from 50-day average
- -3.8%
- Distance from 200-day average
- +0.0%
- RSI (14)
- 40.5
- Relative volume
- 0.69×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 23.2%
- Volatility vs own 5-year history
- 20th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.48
- Correlation with S&P 500
- 0.30
- Current drawdown from 1-year high
- -10.5%
- Maximum drawdown, 3 years
- -37.5%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Dec 30, 2021 | Jul 25, 2024 | -54.3% | 644 days | Not yet recovered |
| Oct 16, 2020 | Oct 30, 2020 | -16.0% | 10 days | 17 days (Nov 24, 2020) |
| Dec 31, 2020 | Mar 18, 2021 | -13.8% | 52 days | 23 days (Apr 21, 2021) |
| Sep 8, 2021 | Oct 4, 2021 | -13.3% | 18 days | 55 days (Dec 21, 2021) |
| Apr 23, 2021 | May 12, 2021 | -10.2% | 13 days | 20 days (Jun 10, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $49.03B
- P/E (TTM)
- 48.9
- EPS, diluted (TTM)
- $1.74
- Revenue (TTM)
- $6.51B
- 52-week range
- $72.30 – $96.29
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $5.23B | $5.38B | $5.01B | $5.44B | $6.07B |
| Gross profit | $4.01B | $4.22B | $3.97B | $4.32B | $4.74B |
| Operating income | $1.61B | $1.70B | $1.43B | $1.38B | $1.64B |
| Net income | $1.50B | $1.52B | $1.40B | $4.17B | $1.07B |
| EPS (diluted) | $2.38 | $2.44 | $2.30 | $6.97 | $1.83 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.35B | $1.39B | $1.41B | $1.53B | $1.55B | $1.57B | $1.65B | $1.74B |
| Net income | $3.07B | $385.6M | $358.0M | $329.8M | $291.1M | $91.2M | $380.7M | $241.9M |
| EPS (diluted) | $5.13 | $0.65 | $0.61 | $0.56 | $0.50 | $0.16 | $0.66 | $0.42 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | $1.73B | $1.22B | $895.8M | $542.3M | $1.60B |
| Capital expenditure | -$329.8M | -$264.8M | -$266.3M | -$252.4M | -$260.2M |
| Free cash flow | $1.40B | $953.4M | $629.5M | $289.9M | $1.33B |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | -$512.8M | -$1.73B | -$879.6M | -$1.16B | -$719.3M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $4.25B
- Total assets
- $13.87B
- Total liabilities
- $3.14B
- Total debt
- $704.4M
- Net debt
- -$2.20B
- Shareholders’ equity
- $10.62B
As of Jun 30, 2026 (filed Aug 4, 2026).
Short interest
- Shares sold short
- 9,088,401
- Days to cover
- 3.15
- Change vs previous report
- +0.7%
FINRA short interest, settlement date Sep 15, 2026.
Stock splits
- Jun 1, 2020
- 3-for-1
- Dec 14, 2015
- 2-for-1
- May 28, 2010
- 2-for-1